In January 2021, PATH, GSK, and Bharat Biotech (BBIL) announced the signing of a product transfer agreement for the RTS,S/AS01 malaria vaccine, following a comprehensive and competitive selection process conducted by GSK and PATH, in consultation with WHO. BBIL will take over the production activities of RTS,S (excluding the adjuvant which will continued to be manufactured by GSK), over time, and become the vaccine’s sole supplier by 2029, at the latest.